Compare 3-D Matrix Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
With a growth in Net Sales of 42.21%, the company declared Outstanding results in Oct 25
4
With ROE of -37.31%, it has a risky valuation with a 5.96 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
JPY 57,702 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.04
0.76%
14.59
Revenue and Profits:
Net Sales:
2,538 Million
(Quarterly Results - Jan 2026)
Net Profit:
652 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.26%
0%
21.26%
6 Months
27.11%
0%
27.11%
1 Year
222.14%
0%
222.14%
2 Years
229.69%
0%
229.69%
3 Years
89.24%
0%
89.24%
4 Years
30.25%
0%
30.25%
5 Years
50.18%
0%
50.18%
3-D Matrix Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.69%
EBIT Growth (5y)
9.33%
EBIT to Interest (avg)
-242.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
1.06
Tax Ratio
0.89%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-15.36
EV to EBITDA
-15.36
EV to Capital Employed
4.40
EV to Sales
2.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-28.64%
ROE (Latest)
-37.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Jan 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jan'26 - YoY
Jan'26
Jan'25
Change(%)
Net Sales
2,538.40
1,785.00
42.21%
Operating Profit (PBDIT) excl Other Income
346.60
-74.10
567.75%
Interest
1.70
17.90
-90.50%
Exceptional Items
-8.00
-5.00
-60.00%
Consolidate Net Profit
652.40
-588.00
210.95%
Operating Profit Margin (Excl OI)
136.60%
-41.50%
17.81%
USD in Million.
Net Sales
YoY Growth in quarter ended Jan 2026 is 42.21% vs 55.49% in Jan 2025
Consolidated Net Profit
YoY Growth in quarter ended Jan 2026 is 210.95% vs -4.83% in Jan 2025
Annual Results Snapshot (Consolidated) - Apr'25
Apr'25
Apr'24
Change(%)
Net Sales
6,934.10
4,588.80
51.11%
Operating Profit (PBDIT) excl Other Income
-1,156.20
-2,117.00
45.38%
Interest
74.40
83.80
-11.22%
Exceptional Items
4.60
-164.80
102.79%
Consolidate Net Profit
-2,501.20
-255.50
-878.94%
Operating Profit Margin (Excl OI)
-166.70%
-461.30%
29.46%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2025 is 51.11% vs 98.30% in Apr 2024
Consolidated Net Profit
YoY Growth in year ended Apr 2025 is -878.94% vs 89.55% in Apr 2024
About 3-D Matrix Ltd. 
3-D Matrix Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






